Sertraline to treat hot flashes
Autor: | Janet H. Senf, Kelly Green Boesen, Paul Gordon, James P. Kerwin |
---|---|
Rok vydání: | 2006 |
Předmět: |
Adult
medicine.medical_specialty genetic structures Population Placebo Severity of Illness Index law.invention Double-Blind Method Randomized controlled trial Hot flash law Sertraline Internal medicine Severity of illness medicine Humans education Aged education.field_of_study Cross-Over Studies business.industry Obstetrics and Gynecology Middle Aged medicine.disease Crossover study Antidepressive Agents Surgery Menopause Treatment Outcome Hot Flashes Female medicine.symptom business medicine.drug |
Zdroj: | Menopause. 13:568-575 |
ISSN: | 1072-3714 |
DOI: | 10.1097/01.gme.0000196595.82452.ca |
Popis: | Objective: To evaluate the effectiveness of a selective serotonin reuptake inhibitor (SSRI) (sertraline) in decreasing hot flashes in a general population of women. Design: A double-blind, placebo-controlled, crossover trial was conducted in a southwestern urban setting. A total of 102 women aged 40 to 65 who were experiencing hot flashes and not taking any hormone therapy were recruited. After 1 week of baseline hot flash data collection, study participants were randomized to receive placebo or active drug (sertraline 50 mg) for 4 weeks. This intervention was followed by a 1-week washout and cross over to the opposite treatment for 4 weeks. The number and severity of hot flashes were measured. Results: One hundred two women were enrolled in the study. Five dropped out before providing baseline data. Of the 97 remaining, 52 were randomized to active drug first and 45 to placebo first. Ten dropped out of the study before completing all 10 weeks, leaving 46 in the active drug-first arm and 41 in the placebo-first arm. At baseline, the mean number of hot flashes reported was 45.6 per week (SD = 29.6), ranging from 2 to 148. During the sertraline phase of the study, women experienced five fewer hot flashes per week than they did on the placebo (P = 0.002). The severity of hot flashes was not significantly different; however, the hot flash score (number average severity) was significantly improved during the sertraline phase. Conclusion: Sertraline reduced the number of hot flashes and improved the hot flash score relative to placebo and may be an acceptable alternative treatment for women experiencing hot flashes. |
Databáze: | OpenAIRE |
Externí odkaz: |